EXHIBIT 10.264
OPTION AGREEMENT
BETWEEN
INVESTORS TRUST & CUSTODIAL SERVICES (IRELAND) LTD.,
AS TRUSTEE FOR ROYALTY PHARMA,
ROYALTY PHARMA FINANCE TRUST
AND
LIGAND PHARMACEUTICALS INCORPORATED
THIS OPTION AGREEMENT (this "AGREEMENT") is made and entered into on this
1st day of October, 2003, among Ligand Pharmaceuticals Incorporated ("SELLER"),
Royalty Pharma Finance Trust, a Delaware Statutory Trust ("BUYER"), and
Investors Trust & Custodial Services (Ireland) Ltd., in its capacity as Trustee
of Royalty Pharma, a unit trust organized under the laws of the Republic of
Ireland ("ROYALTY PHARMA").
Whereas, Seller and Buyer (as the assignee of Pharmaceutical Royalties
International (Cayman) Ltd.) are parties to that certain Purchase Agreement
dated as of March 6, 2002, as amended (the "PURCHASE AGREEMENT"), pursuant to
which Seller agreed, subject to the terms thereof, to sell, transfer, assign and
deliver to Buyer the right to receive from Seller the Applicable Percentage of
the AHP Net Sales and the Applicable Percentage of the Pfizer Net Sales;
Whereas, pursuant to the Purchase Agreement, Buyer had the option to
acquire an Additional Percentage of both AHP Net Sales and Pfizer Net Sales if
Buyer gave notice in respect of and exercised such option by September 30, 2003
(the "SEPTEMBER 2003 OPTION");
Whereas, Buyer did not exercise the September 2003 Option and therefore the
September 2003 Option expired unexercised;
Whereas, Seller desires to sell to Royalty Pharma the October 2003 Option
(as defined below) and Royalty Pharma desires to acquire the October 2003
Option;
Whereas, on the date hereof Seller has amended the Purchase Agreement so as
to amend the remaining options available to Buyer as set forth in the Purchase
Agreement; and
Whereas, Buyer desires that Royalty Pharma acquire the October 2003 Option
from Seller provided that Buyer has the right to acquire such option from
Royalty Pharma in the future;
NOW, THEREFORE, in consideration of the mutual promises and covenants
contained in this Agreement, the parties hereto hereby agree as follows:
1. Seller hereby grants to Royalty Pharma the following option (the
"OCTOBER 2003 OPTION") to acquire rights to receive the following percentage of
both AHP Net
Sales and Pfizer Net Sales on the same terms as described in Section 2.01(a) of
the Purchase Agreement (other than the last sentence thereof). Payment of the
Option Exercise Price specified below represents payment for the percentage of
both the AHP Net Sales and the Pfizer Net Sales.
--------------- --------------- ----------------------- ------------------------
NOTICE DATE EXERCISE DATE OPTION EXERCISE PRICE PERCENTAGE OF BOTH AHP
NET SALES AND PFIZER NET
SALES
--------------- --------------- ----------------------- ------------------------
October 1, 2003 October 1, 2003 $12,500,000 0.700%
--------------- --------------- ----------------------- ------------------------
2. Royalty Pharma hereby exercises the October 2003 Option.
3. Payment of the Exercise Price for the October 2003 Option shall be as
follows: no later than October 31, 2003, Royalty Pharma shall pay or shall cause
to be paid to Seller the Option Exercise Price of $12,500,000 in U.S. dollars by
wire transfer to an account in the United States designated by Seller in
writing.
4. Within ten Business Days after the first commercial sale of: (a) any
lasofoxifene product in the U.S., Royalty Pharma shall pay to Seller an
additional ***; (b) any Product (as defined in the AHP Agreement) containing
bazedoxifene in the U.S. (but not including any such Product described in
subsection (c) of this paragraph), Royalty Pharma shall pay to Seller an
additional ***; and (c) any Product (as defined in the AHP Agreement) containing
both bazedoxifene and Premarin in the U.S., Royalty Pharma shall pay to Seller
an additional ***; provided, however, that no additional payment described in
any of subsections (a)-(c) of this paragraph shall be due and payable to the
extent that the product or Product, as applicable, described in such subsection
is not approved for commercial sale in the U.S. by the U.S. Food and Drug
Administration (the "FDA") on or prior to October 1, 2005.
5. (a) The rights granted to Royalty Pharma upon the exercise of the
October 2003 Option shall expire in accordance with the provisions of Section
2.03 of the Purchase Agreement.
(b) Each of the following provisions contained in the Agreement shall be
incorporated herein by reference, with each reference to Buyer in such
provisions deemed to be amended to be a reference to Royalty Pharma: 2.04 and
2.05 (except that the phrase "except to the extent of the security interest
granted by Seller to Buyer pursuant to Section 2.01(a)" shall be deemed to be
stricken from the first sentence thereof).
6. Royalty Pharma hereby grants to Buyer the right to acquire from Royalty
Pharma, exercisable by notice to Royalty Pharma no later than December 31, 2003,
the right to receive from Seller the percentage of AHP Net Sales and Pfizer Net
Sales acquired pursuant to the October 2003 Option if Buyer either (i) pays the
Option Exercise Price to Seller no later than the date due or (ii) reimburses
Royalty Pharma for payment
***Portions of this page have been omitted pursuant to a request for
Confidential Treatment and filed separately with the Commission.
-2-
of the Option Exercise Price. Royalty Pharma agrees that Buyer has no obligation
to exercise such right.
7. REPRESENTATIONS AND WARRANTIES. Seller hereby makes to Royalty Pharma
the representations and warranties made to Buyer in Sections 3.01, 3.02, 3.03
and 3.04 of the Purchase Agreement with respect to this Agreement to the same
extent made in the Purchase Agreement with respect to such Purchase Agreement;
Royalty Pharma, with respect to itself, hereby makes to Seller the same
representations and warranties made by Buyer to Seller in Sections 4.01, 4.02,
4.03 and 4.04 of the Purchase Agreement with respect to this Agreement as Buyer
made in the Purchase Agreement with respect to the Purchase Agreement.
8. COVENANTS. Seller covenants to and agrees with Royalty Pharma to the
same extent as Seller covenanted to and agreed with Buyer as set forth in
Sections 5.01, 5.04, 5.05, 5.06, 5.07 and 5.08 of the Purchase Agreement,
provided that each reference in any of such Sections to "Section 2.01" or the
Purchase Agreement shall be deemed to be a reference to this Agreement.
9. INDEMNIFICATION. Seller agrees to indemnify Royalty Pharma to the same
extent as Seller has agreed to indemnify Buyer as set forth in Article VI of the
Purchase Agreement, and Royalty Pharma agrees to indemnify Seller to the same
extent as Buyer has agreed to indemnify Seller as set forth in Article VI of the
Purchase Agreement (provided that (a) any reference in such Article VI to
"Article IV", "Section 2.02(b)" or the Purchase Agreement shall be deemed to be
a reference to this Agreement, (b) the reference to the "Exercise Date" in
subsection (iii) of Section 6.01(b) shall be deemed to be a reference to October
31, 2003 and (iii) the proviso at the end of Section 6.01(b) shall be deemed to
be stricken from such Section).
10. DEFINITIONS. All capitalized terms used but not defined herein shall
have the respective meanings ascribed to them in the Purchase Agreement.
11. GOVERNING LAW. This Agreement shall be governed construed in accordance
with and governed by the law of the State of New York.
12. ENTIRE AGREEMENT. This Agreement, together with any provisions
referenced and/or incorporated by reference herein, constitutes the full and
entire understanding between the parties regarding the subject matter herein.
Except as otherwise expressly provided herein, the provisions hereof shall be
binding upon and inure to the benefit of the parties hereto and their respective
successors and assigns. Without limiting the generality of the foregoing,
nothing herein shall prohibit Royalty Pharma from assigning all or any of its
rights or obligations hereunder to Buyer.
13. COUNTERPARTS. This Agreement may be signed in any number of
counterparts, each of which shall be an original, with the same effect as if the
signatures thereto and hereto were upon the same instrument. This Agreement
shall become
-3-
effective when each party hereto shall have received a counterpart hereof signed
by the other party hereto.
14. CAPTIONS. The titles and captions herein are included for convenience
of reference only and shall be ignored in the construction or interpretation
hereof.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
-4-
IN WITNESS WHEREOF, the parties hereof have caused this Option Agreement to
be duly executed and delivered as a deed by their respective authorized officers
of the day and year first written above.
SELLER
------
LIGAND PHARMACEUTICALS INCORPORATED
By: /S/ XXXXXX XXXXXXXX
-----------------------------------
Name: XXXXXX XXXXXXXX
-----------------------------------
Title: VP & GENERAL COUNSEL
-----------------------------------
ROYALTY PHARMA
--------------
INVESTORS TRUST & CUSTODIAL SERVICES (IRELAND) LTD.,
AS TRUSTEE FOR ROYALTY PHARMA
By: /S/ XXXX XXXXXXX
-----------------------------------
Name: XXXX XXXXXXX
-----------------------------------
Title: DIRECTOR
-----------------------------------
BUYER
-----
ROYALTY PHARMA FINANCE TRUST
By: RP Management LLC, as Administrator
/S/ XXXXX XXXXXXXXX
-----------------------------------
Xxxxx Xxxxxxxxx, Member
Signing only with respect to Section 6
